Title: The Use of Human Liver Cell Model and Cytochrome P450 Substrate-Inhibitor Panel for Studies of Dasatinib and Warfarin Interactions.
Authors: Zakharyants, A.; Burmistrova, O.; Poloznikov, A.
Abstract: The possibility of interactions between warfarin and dasatinib and their interactions with other drugs metabolized by cytochrome P450 isoform CYP3A4 was demonstrated using a previously created cytochrome P450 substrate-inhibitor panel for preclinical in vitro studies of drug biotransformation on a 3D histotypical microfluidic cell model of human liver (liver-on-a-chip technology). Dasatinib and warfarin are inhibitors of CYP2C19 isoform and hence, can interfere the drugs metabolized by this isoform. Our findings are in line with the data obtained on primary culture of human hepatocytes and suggest that the model can be used in preclinical in vitro studies of drugs.
Subjects: WARFARIN; MICROFLUIDIC analytical techniques; BIOTRANSFORMATION (Metabolism); HISTOLOGY; DASATINIB; ENZYME inhibitors
Publication: Bulletin of Experimental Biology & Medicine, 2017, Vol 162, Issue 4, p515
ISSN: 0007-4888
Publication type: Academic Journal
DOI: 10.1007/s10517-017-3651-z

The Use of Human Liver Cell Model and Cytochrome P450 Substrate-Inhibitor Panel for Studies of Dasatinib and Warfarin Interactions.

Zakharyants, A.; Burmistrova, O.; Poloznikov, A.